Lapatinib (Lapatinib Ditosylate) Patent Expiration, LOE Window & CMS Spending

Lapatinib (Lapatinib Ditosylate) by Lupin Pharmaceuticals: Multi-Source Generic Molecule, 2 AB generics, $7.0M 2024 CMS Part D & Medicaid spend, and $7,217 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLupin Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$7.0M
2024 Medicare Part D Spend$5.9M
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,217 intro WAC)